Respiratory
The Respiratory Department at St James’s hospital run a number of both investigator-led and industry centered drug trials in respiratory in conjunction with the CRF.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Insmed (ASPEN) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCenter Study to Assess the Efficacy, Safety, and Tolerability of INS1007 Administered Once Daily for 52 Weeks in Subjects with Non-CysticFibrosis Bronchiectasis | Clinical Trial (2020-003688-25) (NCT04594369) | Insmed | Commercial: Industry |
| Thoracic Biobank | Estbalishment of a Thoracic Biobank to use in molecular and Cellular Studies | Prospective Cohort | St. James's Foundation | Non-commercial: Hospital |
| MA39297 | An international trial to characterize the disease behaviour of idiopathic pulmonary fibrosis and interstitial lung disease during the peri-diagnostic period | Clinical Trial (NCT03261037) | F Hoffmann- La Roche Ltd | Commercial: Industry |
| BAL dccr | Airway Gene Expression Profiling and Immune Responses to Lung Disease (BAL) | Observational-non invasive | N/A | Non-commercial: Academic |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Luster | A 52 week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma | Clinical Trial (NCT02555683) (2015-002553-35) | Novartis Pharma UK Ltd | Commercial: Industry |
| GALACTIC-1 | A randomized, double-blind, multicentre, parallel, placebo-controlled study in patients with idiopathic pulmonary fibrosis (IPF) investigating the safety and efficacy of TD139, a dry powder, inhaled galectin-3 inhibitor | Clinical Trial (NCT03832946) (2018-002664-73) | Galecto Biotech AB | Industry |
| Crystal | Crystal - A prospective, multicentre, 12 week, randomized open label study to evaluate the efficacy and safety of glycopyrronium (50 microgrms o.d.) or indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 micrograms o.d.) regarding symptoms and health status in patients with moderate chronic obstructive pulmonary disease (COPD) switching from treatment with any standard COPD regimen | Clinical trial (NCT01985334) | Novartis | Industry |
| Palladium | A multi-centre, randomised, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometason furoate in patients with asthma | Clinical trial (NCT02554786) | Novartis Pharma UK Ltd | Industry |
| IPF/Sarcoidosis | IPF/Sarcoidosis (DCCR) | Observational with radiology or blood tests | DCCR | Non-commercial: Academic |
| IGRA | IGRA (DCCR) | Observational with radiology or blood tests | HSE - Health Protection Surveillance Centre | Non-commercial: Academic |
| INCA | Inhaler Compliance in Asthma (INCA) | Medical device study (NCT01529697) | Health Research Board | Non-commercial: Academic |
| SPICE III | A Prospective Multicentre RCT of Early Goal Directed Sedation Compared with Standard Care in Mechanically Ventilated Patients in Intensive Care | Prospective Cohort (NCT01728558) | ICU Network | Non-commercial: Hospital |
